Lloyds Chemists offers reassurance
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.ALLEN LLOYD, chairman of the fast-growing Lloyds Chemists, has moved to reassure the City after a 40 per cent dive in the value of the shares.
He said that Lloyds 'remains a strong, well-managed company', and he is confident about future prospects.
Investors are concerned that Lloyds is growing too quickly. There are also worries that the company will suffer from a new pricing schedule for some drugs supplied to National Health Service patients.
Yesterday Mr Lloyd promised to consolidate. 'We do not expect to make any issue of new shares in the next 12 months, either to reduce debt or to finance acquisitions,' he said.
He admitted that the new NHS price schedule will reduce Lloyds' annual taxable profits by between pounds 5m and pounds 8m. The admission explains a profit forecast downgrading on Wednesday by Panmure Gordon, Lloyds' stockbrokers. Shares rallied yesterday after the statement and as news spread that Mr Lloyd is coming to London today to give a presentation to investors. They closed at 235p, up 36p.
Mr Lloyd will tell investors that despite the softening of revenues from the NHS, other sales are strong.
In the second half of the financial year to 30 June, turnover in the chemist division rose 9 per cent against the comparable period. Sales were up 6 per cent in Supersave drugstores and were 5 per cent better in the Holland & Barrett health food shops.
Shares also benefited from a positive trading statement from Lloyds's rival, Boots.
Lloyds has promised to pay a 5.55p dividend for the year, up 33 per cent.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments